Sooraj Barjatya and his penchant for heartfelt family dramas were all the rage back in the '90s, and his secret ingredient still works wonders today. The ace director also recently made his OTT ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

Salman Khan and Sooraj Barjatya share a successful partnership, having delivered several hits together. Nearly a decade has passed since their last collaboration, Prem Ratan Dhan Payo (2015).

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

(MENAFN- IANS) Mumbai, Feb 12 (IANS) Filmmaker Sooraj Barjatya recently acknowledged the brilliance of Sanjay Leela Bhansali, stating that he is not a 'visual director' like him. During Barjatya's ...

Sooraj Barjatya revealed that the name 'Prem' became crucial for Rajshri Productions when they were writing 'Maine Pyar Kiya,' and his father suggested it, hoping for success. Salman Khan made the ...

Sooraj Barjatya, director of 'Maine Pyar Kiya' and more, believes re-released romantic films succeed due to their simplicity, a quality often missing in modern movies. He highlighted this in a ...

It was gratifying to see him like my work and want to direct in OTT. Did you ask Sooraj Barjatya why he ventured into OTT? Sooraj sir told me that there’s a lack of family-oriented content on OTT.

In an exclusive interview with Bollywood Bubble, Bollywood director, Sooraj Barjatya speaks about the challenges he faced while filming on the sets of Uunchai. Sooraj Barjatya is one of Bollywood ...

In an exclusive interview with Bollywood Bubble, Bollywood director, Sooraj Barjatya reveals previously unknown details about his debut OTT show, Bada Naam Karega. Sooraj Barjatya is a renowned ...

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates ...